Unknown

Dataset Information

0

Advances in immune checkpoint inhibitors for hepatocellular carcinoma.


ABSTRACT: Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of immune checkpoint blockade in HCC, providing the necessary basis for the rational design of immunotherapy.

SUBMITTER: Han JW 

PROVIDER: S-EPMC10035682 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Advances in immune checkpoint inhibitors for hepatocellular carcinoma.

Han Ji Won JW   Park Su-Hyung SH  

Journal of liver cancer 20210930 2


Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of i  ...[more]

Similar Datasets

| S-EPMC9226303 | biostudies-literature
| S-EPMC6095178 | biostudies-literature
| S-EPMC7944520 | biostudies-literature
| S-EPMC7712941 | biostudies-literature
| S-EPMC7821931 | biostudies-literature
| S-EPMC6394775 | biostudies-literature
| S-EPMC8234948 | biostudies-literature
| S-EPMC10059020 | biostudies-literature
| S-EPMC7678689 | biostudies-literature
| S-EPMC6843273 | biostudies-literature